What is INAB's current stock price?

INAB (IN8bio, Inc.) is currently trading at $1.67 with a market cap of $7.7M.

What sector is IN8bio, Inc. in?

IN8bio, Inc. (INAB) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is INAB a good stock to buy?

Analysts have a Buy consensus on INAB with a price target of $4.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

INAB IN8bio, Inc.

Healthcare

$1.67-0.60%ClosedMarket Cap: $7.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.32

P/S

0.00

EV/EBITDA

0.70

DCF Value

$5.49

FCF Yield

-187.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-96.4%

ROA

-72.3%

ROIC

-76.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.1M	$—
Q4 null	$0.00	$-4.9M	$—
FY null	$0.00	$-19.4M	$—
Q3 null	$0.00	$-3.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$4.00

Target (Median)

$4.00

Target Range

$4.00 - $4.00

1 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-13

Trading Activity

Insider Trades

View All

Rochlin Kateofficer: President and COO

SellTue May 12

McCall Patrickofficer: CHIEF FINANCIAL OFFICER

SellTue May 12

Lamb Lawrenceofficer: EVP and CSO

SellTue May 12

Ho William Tai-Weidirector, officer: CEO

SellTue May 12

Greenwood Lubadirector

SellTue May 12

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.08

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Peers